Video

Talking with Parents about Multisystem Inflammatory Syndrome in Children

Author(s):

Two pediatric cardiologists offer perspective on how to approach conversations about MIS-C with parents or guardians.

In part 2 of an interview with HCPLive, pediatric cardiologists Dongngan Truong, MD, University of Utah Health and Intermountain Primary Children’s Hospital, and Jane Newburger, MD, Boston Children’s Hospital, spoke about the conversations they have with parents about their child’s diagnosis of multisystem inflammatory syndrome (MIS-C).

“Obviously, parents are really concerned and scared and ask about the treatments because this entity has not been around really long,” Truong said.

“I explain to them that we've used these medications before to treat in similar ways to help with the inflammation within the body,” she continued. “[They] have been used in these other things that look similar to MIS-C.”

Newburger mentioned that she first explains MIS-C as a type of “allergic reaction” of the immune system to the coronavirus disease 2019 (COVID-19).

Furthermore, she assures parents it is expected their child will recover — even if the child gets sicker during their hospital stay.

“We use a variety of medications that kind of calm or soothe the immune system,” she noted.

“I also explain that there’s a tremendous amount that we don’t know, that we hope that every child who has MIS-C is involved in research projects that help us treat future children with MIS-C better.”

Go here to watch Part 1.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.